MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Clinical trials for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE explained in plain language.
Never miss a new study
Get alerted when new MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE trials appear
Sign up with your email to follow new studies for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Crohn's sufferers: phase 3 drug trial launches
Disease control Recruiting nowThis study tests a new drug called RO7790121 (Afimkibart) for people with moderate-to-severe Crohn's disease. The goal is to see if it can reduce symptoms and gut inflammation better than a placebo. About 425 adults who haven't responded well to other treatments will take part. T…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 10:54 UTC
-
New hope for kids with Crohn's: drug trial targets gut inflammation
Disease control Recruiting nowThis study tests a new medicine called afimkibart in 100 children aged 2 to 17 with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and help children feel better. Participants will receive either the drug or a placebo, and doctors will mon…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 10:34 UTC
-
New hope for Crohn's sufferers: phase 3 trial of afimkibart launches
Disease control Recruiting nowThis study tests a new drug called RO7790121 (Afimkibart) in 600 people with moderate-to-severe Crohn's disease who haven't responded well to other treatments. Half will get the drug, half a placebo, to see if it can reduce symptoms and heal the gut lining. The goal is to control…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 20, 2026 11:57 UTC